Cyclerion Therapeutics (NASDAQ:CYCN) has completed enrollment for Phase 2 studies testing praliciguat in diabetic nephropathy and heart failure with preserved ejection fraction (HFpEF).
Praliciguat stimulates soluble guanylate cyclase (sGC), a key component of the nitric oxide (NO) signaling pathway. NO is involved in many biological processes, and its deficiency is believed to play a role in a variety of diseases.
Praliciguat is being tested in a Phase 2 dose-ranging study in 156 patients with diabetic neuropathy, and in a Phase 2 study in 196 patients with HFpEF. Cyclerion expects to report data for both studies in the fourth quarter of 2019.
Cyclerion is developing additional sGC stimulator programs including olinciguat, which is in Phase 2 development for sickle cell disease; and IW-6463, which is in Phase 1 development for serious and orphan central nervous system diseases.
“Our team is advancing a pipeline of differentiated and wholly owned sGC stimulator therapeutic candidates with compelling preclinical and clinical data. Each program targets a devastating disease with limited, if any, treatment options,” Peter Hecht, Cyclerion’s CEO, said in a statement.
